Organization
NKGen Biotech
5 clinical trials
Clinical trial
A Phase 1, Open-Label, Dose Escalation Study of Allogeneic Blood-derived Natural Killer Cells to Evaluate Safety and Tolerability in Participants With Pathologically Confirmed Cancer Refractory to Conventional TherapyStatus: Active (not recruiting), Estimated PCD: 2024-08-01
Clinical trial
A Phase 1/2a, Open-Label, Multi-Center Study Evaluating the Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With Ex Vivo Expanded Autologous Natural Killer Cells (SNK01) in Subjects With Advanced/Metastatic EGFR-Expressing CancersStatus: Terminated, Estimated PCD: 2023-09-21
Clinical trial
A Phase I/IIa, Study to Evaluate the Safety, Tolerability and Exploratory Efficacy of SNK01 in Participants With Moderate Alzheimer's DiseaseStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Single Center, Open Label, Phase 1 Study to Evaluate the Safety, Tolerability and Exploratory Efficacy of SNK01 in Subjects With Alzheimer's Disease (AD)Status: Terminated, Estimated PCD: 2023-08-16
Clinical trial
Phase 1, Open-Label, Safety Study of Escalating Doses of Ex Vivo Expanded, Autologous Natural Killer Cells in Patients With Pathologically Confirmed Cancer Refractory to Conventional TherapyStatus: Completed, Estimated PCD: 2023-02-17